QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
NASDAQ:BLU

BELLUS Health Stock Forecast, Price & News

$3.98
+0.13 (+3.38 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.79
Now: $3.98▼
$4.03
50-Day Range
$3.09
MA: $3.69▼
$4.56
52-Week Range
$2.01
Now: $3.98▼
$12.03
Volume1.36 million shs
Average Volume1.73 million shs
Market Capitalization$311.78 million
P/E RatioN/A
Dividend YieldN/A
Beta0.42
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Headlines

RBC Capital Initiates Coverage On BELLUS Health with Outperform Rating, Announces Price Target of $8
January 29, 2021 |  benzinga.com
Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation
January 15, 2021 |  finance.yahoo.com
BELLUS Health to Present at the Eleventh International Virtual Cough Symposium
January 14, 2021 |  finance.yahoo.com
BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with Atopic Dermatitis
December 14, 2020 |  finance.yahoo.com
BELLUS Health Announces First Patient Dosed in its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
December 8, 2020 |  finance.yahoo.com
NASDAQ:BLU (BELLUS Health Inc.)
November 28, 2020 |  fool.ca
BELLUS Health EPS beats by $0.05
November 12, 2020 |  seekingalpha.com
BELLUS Health Reports Third Quarter 2020 Financial Results and Business Highlights
November 12, 2020 |  finance.yahoo.com
Earnings Preview: Bellus Health (BLU) Q3 Earnings Expected to Decline
November 5, 2020 |  finance.yahoo.com
BELLUS Health up 9.8% on Point72 stake disclosure
October 24, 2020 |  seekingalpha.com
Bellus Health under pressure on planned equity offering
October 19, 2020 |  seekingalpha.com
MRNS Oct 2020 4.000 put
October 16, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLU
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.bellushealth.com
Phone450 680 4500
Employees17
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio11.64
Quick Ratio11.64

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$30,000.00
Price / Sales10,392.71
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.57 per share
Price / Book2.54

Profitability

EPS (Most Recent Fiscal Year)($0.55)
Net Income$-25,970,000.00
Net Margins-190,199.98%
Return on Equity-30.46%
Return on Assets-28.77%

Miscellaneous

Outstanding Shares78,337,000
Market Cap$311.78 million
Next Earnings Date2/25/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.84 out of 5 stars

Medical Sector

116th out of 1,958 stocks

Pharmaceutical Preparations Industry

48th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$3.98
+0.13 (+3.38 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLU News and Ratings via Email

Sign-up to receive the latest news and ratings for BLU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BELLUS Health (NASDAQ:BLU) Frequently Asked Questions

Is BELLUS Health a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BELLUS Health stock.
View analyst ratings for BELLUS Health or view top-rated stocks.

What stocks does MarketBeat like better than BELLUS Health?

Wall Street analysts have given BELLUS Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BELLUS Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BELLUS Health?

BELLUS Health saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 1,290,000 shares, a decrease of 15.1% from the December 31st total of 1,520,000 shares. Based on an average daily volume of 1,610,000 shares, the short-interest ratio is presently 0.8 days. Currently, 2.1% of the company's shares are sold short.
View BELLUS Health's Short Interest.

When is BELLUS Health's next earnings date?

BELLUS Health is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for BELLUS Health.

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc. (NASDAQ:BLU) released its earnings results on Tuesday, November, 17th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. BELLUS Health had a negative trailing twelve-month return on equity of 30.46% and a negative net margin of 190,199.98%.
View BELLUS Health's earnings history.

How has BELLUS Health's stock been impacted by Coronavirus?

BELLUS Health's stock was trading at $9.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BLU shares have decreased by 57.7% and is now trading at $3.98.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for BLU?

9 analysts have issued 12-month target prices for BELLUS Health's shares. Their forecasts range from $6.00 to $12.00. On average, they expect BELLUS Health's share price to reach $8.62 in the next year. This suggests a possible upside of 116.5% from the stock's current price.
View analysts' price targets for BELLUS Health or view top-rated stocks among Wall Street analysts.

Who are BELLUS Health's key executives?

BELLUS Health's management team includes the following people:
  • Mr. Roberto Francesco Bellini, Pres, CEO & Director (Age 41)
  • Mr. François Desjardins C.A., CPA, CPA, CA, VP of Fin. (Age 58)
  • Dr. Denis Garceau, Sr. VP of Drug Devel. (Age 64)
  • Dr. Catherine M. Bonuccelli, Chief Medical Officer (Age 63)
  • Mr. Tony Matzouranis, VP of Bus. Devel. (Age 48)
  • Mr. Ramzi Benamar, Chief Financial Officer (Age 48)
  • Mr. Daniel Matthews, Director of Investor Relations & Communications
  • Mr. Sébastien Roy, Corp. Sec. (Age 45)

Who are some of BELLUS Health's key competitors?

Some companies that are related to BELLUS Health include Repare Therapeutics (RPTX), Innoviva (INVA), MacroGenics (MGNX), Annexon (ANNX), Athenex (ATNX), Theravance Biopharma (TBPH), Vanda Pharmaceuticals (VNDA), Veru (VERU), Karyopharm Therapeutics (KPTI), Morphic (MORF), ORIC Pharmaceuticals (ORIC), Akero Therapeutics (AKRO), Avid Bioservices (CDMO), ZIOPHARM Oncology (ZIOP) and Enanta Pharmaceuticals (ENTA).
View all of BLU's competitors.

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), (IPOC), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST).

What is BELLUS Health's stock symbol?

BELLUS Health trades on the NASDAQ under the ticker symbol "BLU."

Who are BELLUS Health's major shareholders?

BELLUS Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Avidity Partners Management LP (7.31%), Artal Group S.A. (6.06%), Orbimed Advisors LLC (5.35%), Janus Henderson Group PLC (2.37%), AWM Investment Company Inc. (0.51%) and Jefferies Group LLC (0.17%).

Which major investors are selling BELLUS Health stock?

BLU stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC.

Which major investors are buying BELLUS Health stock?

BLU stock was acquired by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Artal Group S.A., Janus Henderson Group PLC, AWM Investment Company Inc., Jefferies Group LLC, Laurion Capital Management LP, Renaissance Technologies LLC, and D.A. Davidson & CO..

How do I buy shares of BELLUS Health?

Shares of BLU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BELLUS Health's stock price today?

One share of BLU stock can currently be purchased for approximately $3.98.

How much money does BELLUS Health make?

BELLUS Health has a market capitalization of $311.78 million and generates $30,000.00 in revenue each year. The company earns $-25,970,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does BELLUS Health have?

BELLUS Health employs 17 workers across the globe.

What is BELLUS Health's official website?

The official website for BELLUS Health is www.bellushealth.com.

Where are BELLUS Health's headquarters?

BELLUS Health is headquartered at 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. The company can be reached via phone at 450 680 4500 or via email at [email protected]


This page was last updated on 2/24/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.